Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC

Research output: Contribution to journalJournal article – Annual report year: 2018Researchpeer-review



  • Author: Becker, Juergen C.

    University Hospital Essen, Germany

  • Author: Stang, Andreas

    German Cancer Research Center, Germany

  • Author: zur Hausen, Axel

    Maastricht University Medical Center, Netherlands

  • Author: Fischer, Nicole

    University Medical Center Hamburg-Eppendorf, Germany

  • Author: DeCaprio, James A.

    Dana-Farber Cancer Institute, United States

  • Author: Tothill, Richard W.

    Peter McCallum Cancer Centre , Australia

  • Author: Lyngaa, Rikke

    Section for Immunology and Vaccinology, National Veterinary Institute, Technical University of Denmark, Bülowsvej 27, 1870, Frederiksberg C, Denmark

  • Author: Hansen, Ulla Kring

    University of Washington, United States

  • Author: Ritter, Cathrin

    University Hospital Essen, Germany

  • Author: Nghiem, Paul

    University of Washington, United States

  • Author: Bichakjian, Christopher K.

    University of Michigan, Ann Arbor, United States

  • Author: Ugurel, Selma

    University Hospital Essen, Germany

  • Author: Schrama, David

    University Hospital Würzburg, Germany

View graph of relations

Merkel cell carcinoma (MCC) is a highly aggressive, often lethal neuroendocrine cancer. Its carcinogenesis may be either caused by the clonal integration of the Merkel cell polyomavirus into the host genome or by UV-induced mutations. Notably, virally-encoded oncoproteins and UV-induced mutations affect comparable signaling pathways such as RB restriction of cell cycle progression or p53 inactivation. Despite its low incidence, MCC recently received much attention based on its exquisite immunogenicity and the resulting major success of immune modulating therapies. Here, we summarize current knowledge on epidemiology, biology and therapy of MCC as conclusion of the project 'Immune Modulating strategies for treatment of Merkel Cell Carcinoma', which was funded over a 5-year period by the European Commission to investigate innovative immunotherapies for MCC.
Original languageEnglish
JournalCancer Immunology Immunotherapy
Issue number3
Pages (from-to)341-351
Publication statusPublished - 2018
CitationsWeb of Science® Times Cited: No match on DOI

    Research areas

  • Cell of origin, Epidemiology, IMMOMEC, Immunotherapy, Merkel cell carcinoma, Merkel cell polyomavirus

Download statistics

No data available

ID: 146994703